Surface Oncology Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$63.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Surface Oncology's estimated annual revenue is currently $59.4M per year.(i)
  • Surface Oncology received $35.0M in venture funding in January 2015.
  • Surface Oncology's estimated revenue per employee is $483,065
  • Surface Oncology's total funding is $63.9M.

Employee Data

  • Surface Oncology has 123 Employees.(i)
  • Surface Oncology grew their employee count by 45% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.2M1-99%N/AN/A
#2
$3.1M20233%N/AN/A
#3
$21.5M13918%$351MN/A
#4
$18M1165%$312.8MN/A
#5
$235M418-23%$340.9MN/A
#6
$2.2M3417%N/AN/A
#7
$6M40-9%$176.5MN/A
#8
$109.4M70614%N/AN/A
#9
$6.2M40233%N/AN/A
#10
$1.9M12-20%N/AN/A

Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients anti-tumor immune response. Our broad attack on the TME has the potential to convert patients non-responsive cold tumors into immune-active ones. We are committed to developing a pipeline of next-generation immunotherapies that deliver lasting benefits to patients suffering from cancer as quickly as possible. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. We utilize multiple antibody generation platforms and have established relationships with several best-in-class antibody technology partners. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment. The company has a strategic collaboration with Novartis and is supported by leading healthcare investors, including Atlas Venture, NEA, F-Prime, Lilly Ventures and Amgen Ventures.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$63.9M

Total Funding

123

Number of Employees

$59.4M

Revenue (est)

45%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Surface Oncology News

2022-04-20 - Surface Oncology (NASDAQ:SURF) vs. Monte Rosa ...

Surface Oncology (NASDAQ:SURF) vs. Monte Rosa Therapeutics (NASDAQ:GLUE) Financial Review. Posted by admin on Apr 25th, 2022.

2022-04-17 - Surface Oncology Named one of the 2022 Best Places to ...

Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline...

2022-03-30 - Surface Oncology Reports Inducement Grant under Nasdaq ...

Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline...

2020-08-11 - SURFACE ONCOLOGY, INC. Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2020

CAMBRIDGE, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the second quarter 2020, ...

2019-09-08 - Surface Oncology Inc (NASDAQ:SURF) Short Interest Update

Surface Oncology Inc (NASDAQ:SURF) was the target of a large drop in short interest in the month of July. As of July 31st, there was short ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$19.1M12332%$233M
#2
$20.3M12323%N/A
#3
$15M12413%N/A
#4
$12.8M125-5%N/A
#5
$22.5M125-19%N/A

Surface Oncology Funding

DateAmountRoundLead InvestorsReference
2015-01-09$35.0MAMultipleArticle